By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Cellectis Bioresearch today announced a non-exclusive agreement giving it access to Evrogen's fluorescent proteins.

The deal allows Paris-based Cellectis to incorporate the proteins into its own products, expanding its portfolio of genome engineering tools.

Financial and other terms were not disclosed.

Based in Moscow, Evrogen develops technologies for molecular and cell biology.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Genome Research this week: multiplex genotyping of germline and somatic short tandem repeats, graph-based regularization, and more.

A lack of funding may lead more than two dozen research facilities in Australia to shut down in three months.

Researchers report that paternally inherited genes are more likely to be expressed in mice.

National Institutes of Health Director Francis Collins appears before a House subcommittee to discuss his agency's budget request.